Fairvalue-Calculator Fairvalue-Calculator
EN DE

Myriad Genetics, Inc (MYGN) Fair Value & Analysis

Healthcare · US · Market cap $429M

Price$5.22
Fair Value$5.21
Upside-0.2%
Quality95/100
Evidence: Low Range $3.14 – $6.71

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Myriad Genetics, Inc (MYGN) currently trades at $5.22, while our model-based Fair Value estimate is $5.21 — implying the stock looks roughly 0.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic…

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -96% Danaher Corporation (DHR) -52% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -66% Lonza Group (LZAGY) -59% Agilent Technologies, Inc (A) -54%

Frequently asked questions

Is Myriad Genetics, Inc (MYGN) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $5.21 versus a price of $5.22 — about −0% (overvalued). Model-based estimate, not financial advice.
What is the fair value of MYGN?
Our 21-model fair value for Myriad Genetics, Inc is $5.21 (as of Jun 25, 2026), built from audited fundamentals. The current price is $5.22.
What is the quality score of MYGN?
Myriad Genetics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.